Founded by a group of physicians, CERC has a wide experience in clinical research. Their renown and expertise in this field have enabled them to generate optimal interaction with their industrial partners and other medical research teams focusing on the development of innovative techniques, concepts and treatments.
They provide unparalleled guidance and expert support in a broad range of clinical trials dedicated to the assessment of interventional coronary and peripheral revascularisation, structural and valvular heart disease treatments and adjunctive pharmacology.
Its objectives are to underpin European clinical trials and academic leadership, act as a global CRO and support young scientific leaders.
The CERC’s industrial partners attach great importance to finding cost-effective models which do not compromise quality.
Learn more: www.cerc-europe.org
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
December 13, 2025
Mind Health With 53,000 new cases diagnosed each year, lung cancer is the deadliest cancer in France, according to data from the National Cancer Institute. Three-quarters of cases are detected at an advanced stage, which reduces the chances of recovery. The importance of screening is therefore crucial. In this field, the combination of low-dose CT […]
November 27, 2025
Med City News Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost […]
November 27, 2025
Trial Site News Clinical trial reporting of treatment efficacy is the foundation of public trust in medicine. Yet pharmaceutical companies often report efficacy measured as a relative risk reduction (RRR) while omitting the more relevant absolute risk reduction (ARR). This statistical sleight of hand can make clinically insignificant benefits look spectacular! Consider a simple example A risk is […]